Cure My Disease

Don't miss your cure!

 Log in / Sign up

Targeted radiation zaps childhood brain tumors in early trial

NCT ID NCT07698899

Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This phase 1 trial tests a drug called 177Lu-DTPA-omburtamab, which delivers radiation directly to tumor cells in children and teens with recurrent or refractory medulloblastoma or other central nervous system (CNS) tumors that have spread. The drug targets a protein called B7-H3 found on many cancer cells. The study aims to find the safest dose and check for side effects in up to 18 participants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
177Lu-DTPA-omburtamab
What this could lead to
If it works, this could provide a new treatment option for children with hard-to-treat brain or spinal cord tumors that have come back.
What could go wrong
This is an early phase 1 trial with only 18 participants, so the main goal is safety, not effectiveness. The treatment involves radiation and may cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CENTRAL NERVOUS SYSTEM METASTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

central nervous system primitive neuroectodermal neoplasm ependymoma Ewing sarcoma medulloblastoma neuroblastoma pineoblastoma retinoblastoma rhabdoid tumor rhabdomyosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CENTRAL NERVOUS SYSTEM METASTASIS CNS METASTASES RECURRENT MEDULLOBLASTOMA REFRACTORY MEDULLOBLASTOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    RECRUITING

    New York, New York, 10065, United States

    Contact Phone: •••-•••-••••

  • Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities)

    RECRUITING

    Basking Ridge, New Jersey, 07920, United States

    Contact Phone: •••-•••-••••

  • Memorial Sloan Kettering at Bergen (Limited Protocol Activities)

    RECRUITING

    Montvale, New Jersey, 07645, United States

    Contact Phone: •••-•••-••••

  • Memorial Sloan Kettering at Monmouth (Limited Protocol Activities)

    RECRUITING

    Middletown, New Jersey, 07748, United States

    Contact Phone: •••-•••-••••

  • Memorial Sloan Kettering at Nassau (Limited Protocol Activities)

    RECRUITING

    Uniondale, New York, 11553, United States

    Contact Phone: •••-•••-••••

  • Memorial Sloan Kettering at Suffolk-Commack (Limited Protocol Activities)

    RECRUITING

    Commack, New York, 11725, United States

    Contact Phone: •••-•••-••••

  • Memorial Sloan Kettering at Westchester (Limited Protocol Activities)

    RECRUITING

    Harrison, New York, 10604, United States

    Contact Phone: •••-•••-••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.